Feed aggregator
US FDA approves first drug for fatty liver disease NASH
Reuters was first to report on the FDA approving Madrigal Pharmaceuticals’ drug Rezdiffra, an oral drug to treat a fatty liver disease known as non-alcoholic steatohepatitis (NASH). The approval was the first of its kind.
The post US FDA approves first drug for fatty liver disease NASH appeared first on Reuters News Agency.
Novo Nordisk says experimental drug amycretin show 13% weight loss in trial
Reuters was first to report on the early trial data for Novo Nordisk’s highly anticipated experimental drug amycretin which showed that participants had a weight loss of 13.1% after 12 weeks, prompting the company’s shares to rise to record highs and placing it above Tesla by market valuation.
The post Novo Nordisk says experimental drug amycretin show 13% weight loss in trial appeared first on Reuters News Agency.
Major Bayer shareholder Harris backs CEO’s focus on internal restructuring
Reuters exclusively reported that major Bayer shareholder Harris Associates came out in strong support of the drugmaker’s decision to suspend work on breaking up the diversified group, giving some breathing room to its embattled CEO.
The post Major Bayer shareholder Harris backs CEO’s focus on internal restructuring appeared first on Reuters News Agency.
Eli Lilly could launch obesity drug in India next year
Reuters exclusively reported that U.S. drugmaker Eli Lilly LLY.N expects to launch Mounjaro, its blockbuster diabetes drug and wildly popular obesity treatment, in India as early as next year after it clears an ongoing regulatory review.
The post Eli Lilly could launch obesity drug in India next year appeared first on Reuters News Agency.